SecBot SecBot

PRQR

ProQR Therapeutics N.V.
Nasdaq· Pharmaceutical Preparations· CIK 0001612940 Biotech & Drug Discovery
$1.24 −0.05 (−3.88%)
Oct 26 4:00 PM ET · prev $1.29
Market cap
$187.7M
Micro cap
Consensus
Buy
94% Buy or better · 16 analysts
Median target
$8.00
+545% · range $3.00–10.00
Next earnings
Nov 5
in 9 days · EPS est. −$0.11
1 year
−56.6%
from $2.86 · Oct 27
30 days
−24.8%
from $1.65
52-week range
$1.24–2.86
at the low
Avg volume 20D
923.6K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$1.3M
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL ProQR announced the appointment of Chris Hart (ex-Eli Lilly VP of Data Science) as Chief Data and AI Officer…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $1.3M at an average $1.68. No open-market sales. Price is 26% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 11 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    15 of 16 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.137 → −$0.106 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    32% below its 50-day average. New closing low $1.24 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ADAGE CAPITAL PARTNERS GP, L.L.C.ADD9,015,897$16.8M
Aberdeen Group plcDOUBLED8,932,507$16.6M
MORGAN STANLEYADD1,767,215$3.3M
CITADEL ADVISORS LLCADD1,184,314$2.2M
UBS Group AGDOUBLED639,243$1.2M
JANE STREET GROUP, LLCDOUBLED455,104$846.5K
BNP PARIBAS FINANCIAL MARKETSADD275,631$512.7K
Quadrature Capital LtdDOUBLED84,806$157.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 94% rate it Buy or better
Strong Buy6Buy9Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +545%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 1, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Oct 1, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 20, 2026B of A Securities
INITIATE
INITIATEBuy
Jun 29, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform
Jun 26, 2026Jones Trading
MAINTAIN
MAINTAINBuy
Jun 26, 2026Chardan Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$1.3M
bought · 2 insiders
$0
sold · 0 insiders
−26.1%
vs their $1.68 cost
DateInsiderTypeValue
Jul 31, 2026
de Boer Daniel Anton
Chief Executive Officer
BUY$354.0K
Jul 17, 2026
Filius Bart
Director
BUY$257.9K
Jul 9, 2026
de Boer Daniel Anton
Chief Executive Officer
BUY$261.0K
Jul 7, 2026
de Boer Daniel Anton
Chief Executive Officer
BUY$238.5K
Jun 26, 2026
Filius Bart
Director
BUY$231.0K
Jun 2, 2026
Hinsch Gylvin Lykke
Director
AWARD14,595 sh
Jun 2, 2026
Hinsch Gylvin Lykke
Director
AWARD14,495 sh

Earnings setup

Estimates
Nov 5
reports in 9 days
−$0.11
EPS estimate, this quarter
+23%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.11-$0.11–-$0.10+1.9%$4.9M
Next Q-$0.13-$0.18–-$0.09+2.2%$4.9M
Current FY-$0.45-$0.53–-$0.38+2.1%$20.5M
Next FY-$0.46-$0.54–-$0.39+2.1%$18.4M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 SEC
ProQR announced the appointment of Chris Hart (ex-Eli Lilly VP of Data Science) as Chief Data and AI Officer and…
6-K — Impact 4/10
Sep 9, 2026 SEC
ProQR announced the first participant dosed in the Phase 1 study of AX-0811, a next-generation RNA editing…
6-K — Impact 4/10
Sep 9, 2026 Announcement
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (
Jul 31, 2026 Insider
de Boer Daniel Anton bought 200,000 shares
Chief Executive Officer @ $1.77 ($354.0K)
Jul 17, 2026 Insider
Filius Bart bought 150,000 shares
Director @ $1.72 ($257.9K)
Jul 16, 2026 SEC
ProQR Therapeutics N.V. received SEC effectiveness on July 15, 2026 for its F-3 shelf registration (File No…
EFFECT — Impact 5/10
Jul 9, 2026 Insider
de Boer Daniel Anton bought 150,000 shares
Chief Executive Officer @ $1.74 ($261.0K)
Jun 30, 2026 Inst.
ADAGE CAPITAL PARTNERS GP, — ADD
9,015,897 shares ($16.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
PRQR Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Sep 9, 2026
Announcement
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company…
Jul 30, 2026
Earnings date
PRQR Q2 2026 Earnings Scheduled — 2026-07-30
Jun 25, 2026
Announcement
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage…
Jun 25, 2026
Announcement
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR or the Company), a…
May 6, 2026
Earnings date
PRQR Q1 2026 Earnings Scheduled — 2026-05-06

SecBot reports

10 filings · 4 press releases · 2 bullish · 3 bearish · 1 mixed · 4 neutral
All PRQR filing & press-release reports (14)